Recent advances have seen immuno-therapy become a shining light within oncology research, transforming both the way cancer treatments are viewed and the potential standards of care and outcomes.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
